Valuation: Profound Medical Corp.

Market Cap 372M 264M 232M 217M 199M 25.29B 381M 2.57B 1B 12.52B 991M 970M 43.27B P/E 2026 *
-8.77x
P/E 2027 * -9.86x
Enterprise Value 372M 264M 232M 217M 199M 25.29B 381M 2.57B 1B 12.52B 991M 970M 43.27B EV / Sales 2026 *
10.3x
EV / Sales 2027 * 6.07x
Free-Float
95.93%
Yield 2026 *
-
Yield 2027 * -
1 day-0.29%
1 week+3.85%
Current month+8.59%
1 month+8.94%
3 months+14.41%
6 months+3.23%
Current year-4.92%
1 week 9.52
Extreme 9.52
10.93
1 month 9.31
Extreme 9.31
11.2
Current year 6.52
Extreme 6.52
12.4
1 year 5.23
Extreme 5.23
12.4
3 years 5.23
Extreme 5.23
16
5 years 4.21
Extreme 4.21
22.63
10 years 4.21
Extreme 4.21
36.73
Manager TitleAgeSince
Chief Executive Officer 71 15/08/2016
President 44 07/11/2024
Director of Finance/CFO 58 03/03/2022
Director TitleAgeSince
Chairman 71 -
Director/Board Member 68 14/06/2018
Director/Board Member 79 14/06/2018
Date Insider Type Main position Quantity % Market Cap.
6/29/26 A Option

Director

2,122 0.0058%
6/29/26 A Option

Director

1,763 0.0049%
6/29/26 A Option

Director

1,762 0.0048%
Change 5-day change 1-year change 3-year change Capi.($)
-0.29%+3.85%+35.63%-34.98% 265M
+0.01%+9.50%+19.56%+2.60% 214B
-1.29%+9.69%-5.01%-24.45% 140B
-2.40%+3.64%-28.94%+8.14% 128B
-0.04%+7.14%-56.76%-10.93% 68.46B
+2.49%+1.65%+6.57%+2.41% 48.18B
+4.51%+8.59%-22.65%-28.66% 45.56B
-0.17%+5.13%+17.07%+11.31% 39.69B
-1.15%+2.34%+25.16%+32.79% 37.69B
+2.55%+11.08%-22.83%-3.98% 30.14B
Average +0.40%+6.26%-3.22%-4.58% 75.19B
Weighted average by Cap. -0.20%+7.26%-5.14%-2.93%

Financials

2026 *2027 *
Net sales 36.23M 25.71M 22.59M 21.09M 19.35M 2.46B 37.12M 250M 97.79M 1.22B 96.53M 94.43M 4.21B 61.34M 43.53M 38.25M 35.7M 32.77M 4.17B 62.85M 423M 166M 2.06B 163M 160M 7.13B
Net income -43.53M -30.9M -27.15M -25.34M -23.26M -2.96B -44.61M -300M -118M -1.46B -116M -113M -5.06B -41.11M -29.17M -25.63M -23.93M -21.96M -2.79B -42.12M -284M -111M -1.38B -110M -107M -4.78B
Net Debt - -
Logo Profound Medical Corp.
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Employees
162
Date Price Change Volume
29/07/26 CA$10.24 -0.29% 25,922
28/07/26 CA$10.27 -1.63% 9,762
27/07/26 CA$10.44 +1.56% 45,080
24/07/26 CA$10.28 +6.42% 44,223
23/07/26 CA$9.660 -2.03% 2,305
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
10.24
Average target price
-

Quarterly revenue - Rate of surprise